Researchers in Ann Arbor Michigan and at Cornell University in New York have found that specific types of white blood cells (leukocytes) might be used to predict the disease progression of idiopathic pulmonary fibrosis (IPF). The study appeared in the December 22 issue of…
Idiopathic Pulmonary Fibrosis Progression May Depend on White Blood Cell Type
Columbia University Medical Center and Biogen Idec have established a strategic alliance worth $30 million focused on genetic research with the purpose of discovering underlying disease causes and new therapeutic options. The collaborative program is expected to broaden the knowledge of genomics and genome sequencing, as well as help patients who…
Clinical stage specialty pharmaceutical company Pacific Therpaeutics Ltd. has just obtained licensing for a drug technology that uses a rapid-acting oral disintegrating tablet (ODT), indicated for erectile dysfunction; and together with partner Montreal-based IntelGenx Corporation, a company focused on developing enhanced drug delivery systems, Pacific will be combining two already-approved…
Genkyotex, a company developing selective NOX inhibitors for the treatment of chronic diseases, has completed a $21 million Series D round of financing. The proceeds from the financing will be invested in the company’s phase 2 trial to study GKT137831, a therapy for diabetic nephropathy, a progressive fibrotic disease, as well as idiopathic…
Biopharmaceutical Bristol-Myers Squibb Company and the non-profit organization California Institute for Biomedical Research (Calibr) have established a worldwide research collaboration focused on the development of novel small molecule anti-fibrotic therapies, as well as an exclusive license agreement for the company to develop, manufacture and commercialize preclinical compounds from Calibr that result from the…
A case study confirmed the need for a combined diagnosis approach in patients with pulmonary fibrosis and emphysema (CPFE) in contrast to a simplistic approach to lung function examination in symptomatic smokers. The study, entitled “Lung function testing in COPD: when everything is not so simple” was…
The Coalition for Pulmonary Fibrosis (CPF) recently published an overview of the most important 2014 developments regarding the research and treatment of pulmonary fibrosis (PF). The nonprofit organization, which was founded in 2001 with the purpose of accelerating research to find a cure for the disease, believes that…
A new study provides improved understanding of the challenges faced by people with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers, which could help in the development of supportive care and could also improve quality of life in people afflicted with IPF. The study appeared December 23rd, 2014, in the…
Nanomaterials continue to gain in popularity in technological, biomedical, and many other applications, but their defining small size may pose a significant threat to lung health. Scientists have been concerned with the potential pulmonary toxicity of multi-walled carbon nanotubes (MWCNT) in the context of industrial settings, Back in October, Pulmonary…
A new study on Diffuse Parenchymal Lung Disease (DPLD) entitled “A case of pulmonary fibrosis associated with rheumatoid arthritis, scleroderma sine scleroderma and ANCA associated vasculitis” was published in SpringerPlus by Amritpal Singh Anand from Lakeland Rheumatology, St Joseph, USA, and colleagues. Diffuse parenchymal lung disease…
